|
End-of-day quote
NSE India S.E.
2026-09-21
|
5-day change | 1st Jan Change | ||
| 2,009.30 INR | +0.27% |
|
+1.54% | +47.26% |
| 09-16 | Gilead Sciences Expands Licensing Agreements for HIV Treatment | MT |
| 08-06 | Emcure Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 06, 2026 |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- EMCURE Stock
- Consensus Emcure Pharmaceuticals Limited
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
